New security label from Schreiner MediPharm provides tamper evidence on vials

Drug counterfeiters frequently fill original pharmaceutical containers with ineffective or harmful substitutes. In many cases, tampering with the containers cannot be detected. In the worst case, a falsified medicine may have fatal consequences for the patient to whom it has been administered. A tamper protection label with clear and irreversible first-opening indication that Schreiner MediPharm has developed specifically for vials can help prevent illegal reuse of original containers and protect their integrity.

Clear First-Opening Indication for Small Pharmaceutical Containers

The new security label wraps around the vial up to the level of the cap. To open the vial, a label-integrated tear strip has to be peeled off that cannot be resealed unnoticed. In addition, a warning message clearly indicating that the vial has been opened emerges. This first-opening indication can optionally be augmented by a void effect where previously invisible lettering or symbols separate from an indicator field.

For enhanced security, verification features for proof of authenticity may be incorporated into the label. Furthermore, special features are available such as a detachable documentation label, a transparent inspection window for checking the vial content, a light protection function for sensitive substances, or integrated NFC/RFID chips for digital applications.

Schreiner MediPharm’s new tamper-evident label is especially well-suited for small vials and custom-designed for the respective application. It can be processed in the normal labeling workflow in pharmaceutical production while preserving the product’s branding and design. Pharmaceutical manufacturers benefit from a solution that is precisely adapted to their requirements, easily fits their production processes, and helps protect their supply chain. For healthcare professionals, the label is not only easy to use but, above all, indicates at first glance whether the product is an originally sealed medication. As a result, patients can be protected against the potential administration of ineffective or harmful medications.

Caption: Due to its clear first-opening indication, the new security label from Schreiner MediPharm protects the integrity of vials and helps avoid their illegal reuse.

See also

Schreiner MediPharm and Applied DNA Sciences offer forensic counterfeit-proof feature for pharma labels

Schreiner MediPharm, a Germany-based global provider of specialty pharmaceutical labeling solutions, now offers a new forensic authentication feature for pharmaceutical labels in cooperation with Applied DNA Sciences. SigNature DNA is a high-security feature based on DNA markers with which pharmaceutical manufacturers can protect products against counterfeiting, and patients against potential health risks.

Schreiner MediPharm develops smart blister pack for clinical trial

Schreiner MediPharm has developed a smart blister pack for digital patient compliance monitoring to enhance medication adherence by clinical trial participants. Schreiner MediPharm implemented the smart packaging solution together with the Dutch technology company ECCT (Experts in Communications and Connectivity Technology). Employment of this electronic tool to manage and track processes during clinical trials marks a milestone for the pharmaceutical manufacturer.

Schreiner MediPharm supports Biotest AG with “Late Stage Customization” service for supply chain agility

Flexible production of functional labels successfully addresses market segmentation. Schreiner MediPharm, a Germany-based global provider of specialty pharmaceutical labeling solutions for over 65 years, recently implemented a special Late Stage Customization service in partnership with its customer, Biotest AG. The new process allows for faster production of functional labels on short demand. As a result, Biotest benefits from greater flexibility and is able to respond to market requirements with requisite agility, while Schreiner MediPharm assists its customer in meeting the demands of current segmentation trends in the pharmaceutical industry.

  • Jo Webb
  • Product Info
  • English
  • Created 24 Feb 2022
  • Modified 01 Mar 2022
  • Hits 562